{
  "meta": {
    "timestamp": "2025-01-06T10:00:41.566040",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Insulet Corp",
      "symbol": "PODD",
      "analysis": {
        "historical": {
          "risk_score": 50,
          "key_risks": [
            "Supply chain vulnerabilities due to global disruptions",
            "Regulatory risks from delays in FDA or CE Mark approvals",
            "Competitive pressures from established players and startups",
            "Pricing and reimbursement challenges in the U.S.",
            "Ongoing legal risks from intellectual property disputes"
          ],
          "controversies": [
            "Trade secret misappropriation case against EOFlow Co.",
            "Potential intellectual property theft risks in the medical device sector"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Patient-centric focus on improving quality of life for diabetes patients"
          ],
          "governance_issues": [
            "Regulatory compliance in a highly regulated industry"
          ],
          "recommendation": "caution",
          "confidence_score": 75
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Insulet Corporation - CORRECTING and REPLACING Insulet Reports Full ...",
              "snippet": "About Insulet Corporation: ... the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions and estimates and are not intended to be a guarantee of future events or performance. ... delays in clinical trials, and other impacts to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:12.986559+00:00",
              "published_date": null,
              "source_hash": "25b8a8e5ea13eb346087312e190c3222"
            },
            {
              "url": "",
              "title": "Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift ...",
              "snippet": "On Tuesday, Blue Orca Capital released a report on Insulet Corporation (NASDAQ:PODD), saying it is short on the insulin delivery patch pump manufacturer. The report added that Blue Orca is long on ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370480+00:00",
              "published_date": null,
              "source_hash": "1b87d9cf193e14a8be8fdbf2246d6914"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Submitter Name: Insulet Corporation Submitter Address: 100 Nagog Park Acton, MA 01720 FDA Establishment Owner/Operator Number: 9056196 FDA Establishment Registration Number: 3014585508 Primary Contact Person Phone: Fax: Alexander Hamad Manager, Regulatory Affairs 978-600-2432 978-600-0120 Secondary Contact Person Phone: Fax: Lavanya Ramnath",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:12.986681+00:00",
              "published_date": null,
              "source_hash": "e85a9b48e7fcb18cd82b2f0720cb18c2"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Insulet Corporation Q2 2023 Earnings August 8, 2023 Christian D ... the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions and estimates and are not ... delays in clinical trials, and other impacts to the business, our ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:12.986692+00:00",
              "published_date": null,
              "source_hash": "e1bf279d78b8fb10cee363cb534bef08"
            },
            {
              "url": "",
              "title": "Insulet Corporation - Insulet Reports Third Quarter 2024 Revenue ...",
              "snippet": "Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod \u00ae brand of products, today announced financial results for the three months ended September 30, 2024. \"We continue to achieve significant milestones and robust revenue growth,\" said Jim Hollingshead, President and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:12.986702+00:00",
              "published_date": null,
              "source_hash": "45aefdfb40ff54c5b3bdd7113e52cbca"
            },
            {
              "url": "",
              "title": "U.S. Regulatory Approval of Omnipod 5 Reinforces Insulet's Narrow ...",
              "snippet": "Most recently, Insulet received FDA approval on its own hybrid closed-loop Omnipod 5 in early 2022, which will include the ability to control the pump from an Android smartphone and offer ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:12.986727+00:00",
              "published_date": null,
              "source_hash": "4e53bbb32b5336218d4a9c3d38ccf6bc"
            },
            {
              "url": "",
              "title": "Insulet gets FDA warning letter over some insulin pumps",
              "snippet": "Insulet Corp said on Wednesday it received a warning letter from the U.S. Food and Drug Administration over some of the company's insulin pumps.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:12.986738+00:00",
              "published_date": null,
              "source_hash": "e6d713e48cc96d233ac541d0864933dc"
            },
            {
              "url": "",
              "title": "Buy Rating on Insulet: Early FDA Approval and Market Dominance Signal ...",
              "snippet": "Insulet (PODD) Company Description: Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:12.986747+00:00",
              "published_date": null,
              "source_hash": "425c072761f22ded6adf06d7aabeac63"
            },
            {
              "url": "",
              "title": "Insulet Corp | Reuters",
              "snippet": "Insulet Corp reported first-quarter profit that missed market expectations on Thursday, weighed by higher marketing expenses, sending shares of the medical device maker down 3.7% in extended trading.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:12.986756+00:00",
              "published_date": null,
              "source_hash": "2625ae4914b281f1c536c7f007bcaa3d"
            },
            {
              "url": "",
              "title": "Insulet Corporation - Investor Relations",
              "snippet": "Insulet Corporation is an innovative medical device company based in Acton, Massachusetts. It was founded in 2000 with the mission of improving the lives of people with diabetes. Specifically, through our revolutionary Omnipod Insulin Management System, we seek to expand the use of insulin pump therapy. Learn More",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:12.986764+00:00",
              "published_date": null,
              "source_hash": "668d122d542f4e5b8dc2f9c73c717cd1"
            },
            {
              "url": "",
              "title": "Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes",
              "snippet": "Insulet Corp.'s PODD groundbreaking Omnipod 5 Automated Insulin Delivery (\"AID\") system (Omnipod 5) received the FDA's approval for use by type 2 diabetes patients (ages 18 years and above).",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:16.132700+00:00",
              "published_date": "2024-08-27T17:15:00+00:00",
              "source_hash": "552746ae39dafa90285908e832dadd74"
            },
            {
              "url": "",
              "title": "Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court",
              "snippet": "Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod\u00ae brand of products, announced that it has successfully defended ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:24.961434+00:00",
              "published_date": "2024-12-04T13:28:00+00:00",
              "source_hash": "e2a33bf3d4140267f1ab5700554ac76d"
            },
            {
              "url": "",
              "title": "Insulet's Strong International Performance and Optimistic Type 2 Diabetes Market Outlook Drive Positive Analyst Rating",
              "snippet": "This projection is supported by the SECURE-T2D trial and the demonstrated clinical benefits, which are anticipated to drive rapid FDA approval ... Insulet (PODD) Company Description: Insulet Corp ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp regulatory approval delays",
              "retrieved_at": "2025-01-06T17:00:16.132768+00:00",
              "published_date": "2024-12-12T04:26:00+00:00",
              "source_hash": "2246b9e93f8f97676b959f9d21239a5b"
            },
            {
              "url": "",
              "title": "Insulet Corporation - Insulet Reports Third Quarter 2024 Revenue ...",
              "snippet": "Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod \u00ae brand of products, today announced financial results for the three months ended September 30, 2024. ... supply chain disruptions, delays in clinical trials, and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548375+00:00",
              "published_date": null,
              "source_hash": "0b1ce4a5a2c7014eac736db893eaf938"
            },
            {
              "url": "",
              "title": "Insulet Corporation: Business Model, SWOT Analysis, and ... - PitchGrade",
              "snippet": "Insulet must navigate complex regulatory landscapes in different regions, which can be time-consuming and costly. Supply Chain Vulnerabilities: Insulet's manufacturing and supply chain operations are critical to its success. Disruptions in the supply chain, such as shortages of raw materials or production delays, could affect the company's ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548423+00:00",
              "published_date": null,
              "source_hash": "adfe2f2957d51470fc58ca9961da2d04"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Insulet Corporation Q4 2023 Earnings February 22, 2024 Christian Podder Since 2020. 2 Forward Looking Statement ... supply chain disruptions, delays in clinical trials, and other impacts to the business, our customers, suppliers, and employees; international business risks, including regulatory, commercial and logistics risks; the potential ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548448+00:00",
              "published_date": null,
              "source_hash": "c27cb6e1feaa6f443d32d4b94f3fdf56"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Insulet Corporation. Q3 2023 Earnings. November 2, 2023. Christian D. Podder Since 2020. 2. Forward Looking Statement. ... supply chain disruptions, delays in clinical trials, and other impacts to the business, our customers, suppliers, and employees; dependence on a principal product platform; ability to maintain and grow our customer base ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548455+00:00",
              "published_date": null,
              "source_hash": "1ba74166eccfbf8ae185d9b095dfbe10"
            },
            {
              "url": "",
              "title": "Insulet Corporation - CORRECTING and REPLACING Insulet Reports Full ...",
              "snippet": "About Insulet Corporation: ... supply chain disruptions, delays in clinical trials, and other impacts to the business, our customers, suppliers, and employees; dependence on a principal product platform; ability to maintain and grow our customer base; ability to scale the business to support revenue growth; maintenance of an effective sales ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548461+00:00",
              "published_date": null,
              "source_hash": "2dfa619e2fcb847e1191b3ebb3c9dc15"
            },
            {
              "url": "",
              "title": "Insulet Stock Gains From Expansion Strategies, Innovation - MSN",
              "snippet": "Insulet is incurring higher costs associated with Omnipod 5 production. Added to this, supply-chain disruptions and labor shortages continue to put pressure on margins.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548467+00:00",
              "published_date": null,
              "source_hash": "6a3a781fabe6c7606fbeac98a98ab340"
            },
            {
              "url": "",
              "title": "Insulet Stock Gains From Expansion Strategies, Innovation",
              "snippet": "Insulet is incurring higher costs associated with Omnipod 5 production. Added to this, supply-chain disruptions and labor shortages continue to put pressure on margins.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548473+00:00",
              "published_date": null,
              "source_hash": "899933be27db5a6d270d1dff45756da7"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Insulet Corporation. Q1 2023 Earnings. May 4, 2023. Christian D. ... COVID-19 global pandemic, government actions and restrictive measures implemented in response, supply chain disruptions, delaysin clinical trials, and other impacts to the business, our customers, suppliers, and employees; dependence on a principal product platform; ability to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548478+00:00",
              "published_date": null,
              "source_hash": "779250d849145546644d22194483ebbc"
            },
            {
              "url": "",
              "title": "Document - SEC.gov",
              "snippet": "Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. ... supply chain disruptions, delays in clinical trials, and other impacts to the business; dependence on a principal ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548484+00:00",
              "published_date": null,
              "source_hash": "b05e3cc49f77517e34935d43d947e820"
            },
            {
              "url": "",
              "title": "Insulet Corporation - 10K - Annual Report - February 24, 2022 - Fintel",
              "snippet": "Insulet Corporation (\"we\" or the \"Company\") ... supply chain disruptions, labor shortages, inflation and disruption in the financial markets globally. As a result, consumers may reduce their spending, new orders for our Omnipod System may decline and our user attrition rate may increase, which could have a material adverse effect on our ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:17.548489+00:00",
              "published_date": null,
              "source_hash": "a8b244f52d66f55c831e85aadb1e433d"
            },
            {
              "url": "",
              "title": "Navigating Supply Chain Disruptions During Peak Seasons and Beyond",
              "snippet": "Supply chain disruptions throughout 2024 highlighted the risks of relying too heavily on one supply strategy. Incidents such as the Red Sea attacks, Ever Given blockage of the Suez Canal and the Panama Canal drought caused panic among shippers waiting for their goods to arrive.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:21.031883+00:00",
              "published_date": "2024-12-27T05:36:00+00:00",
              "source_hash": "a94f880091ce6206a45cc009aa2bac53"
            },
            {
              "url": "",
              "title": "Should You Continue to Retain Insulet Stock in Your Portfolio Now?",
              "snippet": "Insulet Corporation's ... exert pressure on prices, dent supply, and lengthen the sales cycle. The company faces challenges stemming from the global supply chain disruption, while its sole ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:21.031945+00:00",
              "published_date": "2024-12-09T13:32:00+00:00",
              "source_hash": "13b4debdf7881cbaea98a7590a307300"
            },
            {
              "url": "",
              "title": "Is Insulet Stock Outperforming the Dow?",
              "snippet": "Valued at a market cap of $18.5 billion, Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The Massachusetts-based ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Insulet Corp Insulet Corp supply chain disruptions",
              "retrieved_at": "2025-01-06T17:00:21.031958+00:00",
              "published_date": "2024-12-27T17:20:00+00:00",
              "source_hash": "ac5e1071b2edbaed8ecd1efe8caa4cce"
            },
            {
              "url": "",
              "title": "Insulet Corporation Wins $452 Million in Trade Secret Lawsuit Against ...",
              "snippet": "Boston, MA \u2014 Insulet Corporation, a major player in medical device manufacturing, recently secured a monumental legal victory in the U.S. District Court for the District of Massachusetts. The jury found that competitors EOFlow Co., Ltd. among others had illegally used Insulet's closely guarded trade secrets, awarding the company a ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370415+00:00",
              "published_date": null,
              "source_hash": "3ac4142ee996ac6229d3dc9ec6b681c5"
            },
            {
              "url": "",
              "title": "Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets ...",
              "snippet": "Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370456+00:00",
              "published_date": null,
              "source_hash": "bc01e421992c8f73d5f5b91b1b838495"
            },
            {
              "url": "",
              "title": "Goodwin Secures $452 Million Trade Secret Award for Insulet Corporation ...",
              "snippet": "The IP Litigation team secured a unanimous verdict for Insulet Corporation in a trade secret misappropriation case against EOFlow Co. (Insulet Corporation v. EOFlow Co., Ltd., et al) concerning multiple trade secrets owned by Insulet relating to Insulet's insulin patch pump, the Omnipod. The jury found that EOFlow and its CEO misappropriated four of Insulet's trade secrets, awarding ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370465+00:00",
              "published_date": null,
              "source_hash": "bd307f491ccc429fe645f055976d5d64"
            },
            {
              "url": "",
              "title": "Insulet awarded $452M in EOFlow patent fight | MedTech Dive",
              "snippet": "A federal jury on Tuesday awarded Insulet $452 million in its patent skirmish with EOFlow over insulin patch pumps. The jury awarded Insulet $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages for willful and malicious misappropriation. A judge has not yet entered a judgment on the decision.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370473+00:00",
              "published_date": null,
              "source_hash": "4120eb173e6c48852f06a448bf866e57"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "ees who retained \"Insulet's confidential documents\" that \"fall within the statutory definition of trade secret,\"and (3) that irreparable harm to Insulet crystallized when EOFlow announced an intended acquisition by Medtronic, which \"would be a source of capital for EOFlow\" and in-crease competition with Insulet. Id. at 5\u221222.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370486+00:00",
              "published_date": null,
              "source_hash": "c7bbac641a339556fad7bd150b841be1"
            },
            {
              "url": "",
              "title": "Insulet Corporation v. EOFlow Co. Ltd., et al. - Analysis Group",
              "snippet": "Analysis Group was retained to work with counsel at Goodwin Procter and Insulet Corporation (Insulet), the plaintiff in a trade secret misappropriation matter against EOFlow Co., its related entities, and certain employees (EOFlow). Insulet, which manufactures tubeless wearable insulin delivery devices, alleged that three former employees, who ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370493+00:00",
              "published_date": null,
              "source_hash": "c248f38b6a3cf5247ecd087889befd14"
            },
            {
              "url": "",
              "title": "Federal Judge Keeps Core Allegations Alive in Insulet Corp. Trade ...",
              "snippet": "Boston, MA - In a recent legal development, a federal judge in Massachusetts has decided not to dismiss certain allegations in a lawsuit filed by Insulet Corp. against a South Korean manufacturer of insulin pump patches. The core of the dispute revolves around Insulet Corp.'s allegations that the defendant unlawfully appropriated trade secrets.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370498+00:00",
              "published_date": null,
              "source_hash": "726b9d86a7e994876fd1978590406561"
            },
            {
              "url": "",
              "title": "Insulet Corporation - Insulet Successfully Defends its Intellectual ...",
              "snippet": "Jury awards $452M in damages Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod \u00ae brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (\"EOFlow\") in federal court. After a four-week trial in the U.S. District Court for the District of Massachusetts in ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370503+00:00",
              "published_date": null,
              "source_hash": "c4a2b623bea7ff6a9fafc3a33826f70f"
            },
            {
              "url": "",
              "title": "Insulet Successfully Defends its Intellectual Property Against EOFlow ...",
              "snippet": "Jury awards $452M in damages. ACTON, Mass.--(BUSINESS WIRE)--Dec. 4, 2024-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod \u00ae brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (\"EOFlow\") in federal court. ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:22.370510+00:00",
              "published_date": null,
              "source_hash": "39746d4a26a306da7936743a79122ac8"
            },
            {
              "url": "",
              "title": "Insulet Corp. stock outperforms competitors despite losses on the day",
              "snippet": "Insulet Corp. closed $14.65 short of its 52-week high ($279.77), which the company reached on December 12th.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:24.961398+00:00",
              "published_date": "2024-12-27T22:15:00+00:00",
              "source_hash": "271c950f24c93a0584e56deb8aed7f4e"
            },
            {
              "url": "",
              "title": "Is Insulet Stock Outperforming the Dow?",
              "snippet": "Valued at a market cap of $18.5 billion, Insulet Corporation (PODD) develops ... To confirm its bullish price trend, PODD has been trading above its 200-day and 50-day moving average since late August. PODD released its Q3 earnings results on Nov. 7 ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:24.961425+00:00",
              "published_date": "2024-12-27T13:15:43+00:00",
              "source_hash": "ad1f928350a209d53ccf41a44c780e6a"
            },
            {
              "url": "",
              "title": "Insulet Corp Reaches Analyst Target Price",
              "snippet": "In recent trading, shares of Insulet Corp (Symbol: PODD) have crossed above the average analyst 12-month target price of $250.75, changing hands for $268.00/share. When a stock reaches the target ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:24.961442+00:00",
              "published_date": "2024-11-11T15:31:00+00:00",
              "source_hash": "2c9cea542331bb2a0c920b598e755211"
            },
            {
              "url": "",
              "title": "Insulet Corporation (NASDAQ:PODD) Delivered A Better ROE Than Its Industry",
              "snippet": "We'll use ROE to examine Insulet Corporation (NASDAQ:PODD), by way of a worked example. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Insulet Corp Insulet Corp pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:00:24.961452+00:00",
              "published_date": "2024-12-19T00:00:00+00:00",
              "source_hash": "ed6bb54b753725ca48655c2a97487dff"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Insulet Corp regulatory approval delays",
              "rationale": "Investigate potential delays in obtaining regulatory approvals for new products or markets",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Insulet Corp supply chain disruptions",
              "rationale": "Examine recent supply chain issues and their impact on production and delivery",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Insulet Corp pricing and reimbursement controversies",
              "rationale": "Explore any controversies related to pricing strategies and reimbursement challenges in key markets",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T10:00:41.566050",
        "data_confidence": 75,
        "pattern_confidence": null
      }
    }
  ]
}